Zuellig Pharma Enhances Partnership With Karo Healthcare In Asia

In a significant move to enhance healthcare solutions across Asia, Zuellig Pharma has recently announced the expansion of its commercialisation partnership with Karo Healthcare, a prominent European consumer healthcare company. This collaboration marks a pivotal step in making over-the-counter (OTC) healthcare products more accessible across the region, particularly Lamisil®, a renowned product for treating fungal infections.

Zuellig Pharma, with its extensive network and expertise in the healthcare sector, will serve as the exclusive commercialisation partner for Lamisil® in several key Asian markets, including Hong Kong, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Vietnam. This partnership leverages Zuellig Pharma's industry-leading coverage across healthcare professionals and retail pharmacies through its commercial division, ZP Therapeutics.

Since 2019, Zuellig Pharma has maintained a robust commercialisation partnership with Karo for its product portfolio in the Philippines, Vietnam, Singapore, and Indonesia. The expansion of this partnership underscores both companies' commitment to improving healthcare access and availability in Asia.

John Graham, Group CEO of Zuellig Pharma, expressed enthusiasm about the collaboration. "We are excited to work with Karo to expand access and availability of its products. As an integrated healthcare solutions company, this partnership will also play a key role in the strengthening of Zuellig Pharma's consumer health portfolio as we grow in key markets such as Korea and Taiwan," he stated. Graham further highlighted the importance of ZP Therapeutics' extensive partner network and commercial expertise in facilitating greater access to in-demand consumer healthcare products across Asia.

The strategic alliance between Zuellig Pharma and Karo Healthcare is poised to significantly impact the availability of essential healthcare products in Asia. By combining their strengths, both companies aim to meet the growing demand for effective healthcare solutions across the continent.

Founded in 1987 and headquartered in Stockholm, Sweden, Karo Healthcare has established itself as a leading player in the consumer healthcare industry with its products available in more than 90 countries worldwide. This partnership with Zuellig Pharma not only reinforces Karo's commitment to global health but also strengthens its presence in the Asian market.

Zuellig Pharma's initiative to expand its partnership with Karo Healthcare reflects its dedication to enhancing healthcare accessibility and quality across Asia. Through this collaboration, both companies are set to make significant strides in meeting the healthcare needs of millions across the continent.